Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.

[1]  C. Rountree,et al.  c‐Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma , 2011, Hepatology.

[2]  Jianjun Gao,et al.  Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. , 2011, Bioscience trends.

[3]  Y. Inagaki,et al.  c-Met: A potential therapeutic target for hepatocellular carcinoma. , 2011, Drug discoveries & therapeutics.

[4]  M. Makuuchi,et al.  Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[6]  P. Song,et al.  The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. , 2010, Bioscience trends.

[7]  M. Fukayama,et al.  Sarcomatous change of hepatocellular carcinoma in a patient undergoing living donor liver transplantation. , 2010, Bioscience trends.

[8]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[9]  A. Santoro,et al.  ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). , 2010 .

[10]  S. Jeay,et al.  ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.

[11]  T. Yap,et al.  Targeting the HGF/c-Met Axis: State of Play , 2010, Molecular Cancer Therapeutics.

[12]  N. Kokudo,et al.  Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. , 2010, Bioscience trends.

[13]  P. Chow,et al.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.

[14]  M. Hollenberg,et al.  Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. , 2009, Carcinogenesis.

[15]  S. Giulini,et al.  MicroRNA‐23b mediates urokinase and c‐met downmodulation and a decreased migration of human hepatocellular carcinoma cells , 2009, The FEBS journal.

[16]  Bin Xie,et al.  [The effect of hepatitis B virus X protein on the c-met promoter activity in HepG2 cells]. , 2009, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[17]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[18]  P. Kaposi-Novák.  [Comparative genomic classification of human hepatocellular carcinoma]. , 2009, Magyar onkologia.

[19]  K. Sugimachi,et al.  Impact of Des-Gamma-Carboxy Prothrombin and Tumor Size on the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation , 2009, Transplantation.

[20]  Jia Fan,et al.  Role of overexpression of CD151 and/or c‐Met in predicting prognosis of hepatocellular carcinoma , 2009, Hepatology.

[21]  Ming-Hui Chen,et al.  Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. , 2008, Life sciences.

[22]  T. Burke,et al.  Grb2 signaling in cell motility and cancer , 2008, Expert opinion on therapeutic targets.

[23]  Wei Tang,et al.  Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance. , 2008, Bioscience trends.

[24]  S. Osada,et al.  Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. , 2008, Hepato-gastroenterology.

[25]  P. Liang,et al.  Prognostic Factors and Recurrence of Small Hepatocellular Carcinoma after Hepatic Resection or Microwave Ablation: A Retrospective Study , 2008, Journal of Gastrointestinal Surgery.

[26]  Toshiaki Tanaka,et al.  Coupling of Grb2 to Gab1 Mediates Hepatocyte Growth Factor-induced High Intensity ERK Signal Required for Inhibition of HepG2 Hepatoma Cell Proliferation* , 2008, Journal of Biological Chemistry.

[27]  S. Giulini,et al.  In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. , 2007, International journal of oncology.

[28]  X. Qu,et al.  China-Japan enhance joint research cooperation for drug discoveries and development: News from CJMWDDT 2007 in Jinan, China. , 2007, Drug discoveries & therapeutics.

[29]  Y. Sugiyama,et al.  High-resolution mapping of copy number aberrations and identification of target genes in hepatocellular carcinoma. , 2007, Bioscience trends.

[30]  J. Trepel,et al.  Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. , 2007, Cancer research.

[31]  Yi Sun.  E3 ubiquitin ligases as cancer targets and biomarkers. , 2006, Neoplasia.

[32]  Zhi-min Ma,et al.  [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma]. , 2006, Zhonghua wai ke za zhi [Chinese journal of surgery].

[33]  谢斌,et al.  Expression and clinical significance of c-met, E-cadherin, β-catenin in metastasis of human hepatocellular carcinoma , 2006 .

[34]  Chaojun Li,et al.  Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo , 2005, Molecular Cancer Therapeutics.

[35]  Junhong Han,et al.  Hepatocyte Growth Factor Induces Redistribution of p21CIP1 and p27KIP1 through ERK-dependent p16INK4a Up-regulation, Leading to Cell Cycle Arrest at G1 in HepG2 Hepatoma Cells* , 2005, Journal of Biological Chemistry.

[36]  Phillip D. Zamore,et al.  Ribo-gnome: The Big World of Small RNAs , 2005, Science.

[37]  Y. Shiratori,et al.  Des-γ-carboxy Prothrombin Is a Potential Autologous Growth Factor for Hepatocellular Carcinoma* , 2005, Journal of Biological Chemistry.

[38]  K. Miyazawa,et al.  Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2. , 2004, Journal of biochemistry.

[39]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[40]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[41]  S. Thorgeirsson,et al.  STAT-3 activity in chemically-induced hepatocellular carcinoma. , 2003, European journal of cancer.

[42]  Q. Xie,et al.  [Influence of the inhibitor of c-Met on the growth and motility of hepatocellular carcinoma cells]. , 2003, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[43]  B. Neel,et al.  The "Gab" in signal transduction. , 2003, Trends in cell biology.

[44]  A. Bell,et al.  A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. , 2002, Molecular cell.

[45]  K. Miyazawa,et al.  High Intensity ERK Signal Mediates Hepatocyte Growth Factor-induced Proliferation Inhibition of the Human Hepatocellular Carcinoma Cell Line HepG2* , 2001, The Journal of Biological Chemistry.

[46]  L. Ferrell,et al.  Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.

[47]  Z. Yao,et al.  Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions* , 2001, The Journal of Biological Chemistry.

[48]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[49]  Nakopoulou,et al.  c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinoma , 2000, Histopathology.

[50]  D. Stolz,et al.  Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.

[51]  N. Sadick,et al.  Estrogen and progesterone receptors: their role in postsclerotherapy angiogenesis telangiectatic matting (TM). , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[52]  H. Kawasaki,et al.  Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. , 1999, Liver.

[53]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[54]  Ding‐Shinn Chen,et al.  Hepatocyte Growth Factor Stimulates the Growth and Activates Mitogen-Activated Protein Kinase in Human Hepatoma Cells , 1998, Journal of Biomedical Science.

[55]  M. Takahashi,et al.  Hepatocyte growth factor stimulates DNA synthesis in rat preneoplastic hepatocytes but not in liver carcinoma cells. , 1998, Gastroenterology.

[56]  A. Bardelli,et al.  Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential , 1997, Oncogene.

[57]  D. Seol,et al.  Co‐expression and regulation of Met and Ron proto‐oncogenes in human hepatocellular carcinoma tissues and cell lines , 1997, Hepatology.

[58]  S. Thorgeirsson,et al.  Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Fujimoto,et al.  Expression of hepatocyte growth factor and its receptor c‐met proto‐oncogene in hepatocellular carcinoma , 1997, Hepatology.

[60]  Steven E. Wilson,et al.  Expression of HGF, Its Receptor c-met, c-myc, and Albumin in Cirrhotic and Neoplastic Human Liver Tissue , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[61]  J. Rubin,et al.  Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[62]  S. Thorgeirsson,et al.  Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[63]  M. Fiorentino,et al.  Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c‐met does , 1996, Hepatology.

[64]  D. Erdmann,et al.  Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.

[65]  N. Enomoto,et al.  Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. , 1996, Journal of hepatology.

[66]  T. Shirai,et al.  Hepatocyte Growth Factor Enhancement of Preneoplastic Hepatic Foci Development in Rats Treated with Diethylnitrosamine and N‐Ethyl‐N‐hydroxyethylnitrosamine , 1995, Japanese journal of cancer research : Gann.

[67]  G. Michalopoulos,et al.  Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. , 1995, Carcinogenesis.

[68]  N. Hayashi,et al.  Expression of the c‐met protooncogene in human hepatocellular carcinoma , 1994, Hepatology.

[69]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[70]  K. Annen.  [Analysis of the hepatocyte growth factor receptor in regeneration and oncogenesis of hepatocytes]. , 1994, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[71]  L. Orci,et al.  Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor , 1991, Cell.

[72]  A. Bardelli,et al.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.

[73]  Toshikazu Nakamura,et al.  Marked increase of HGF mRNA in non-parenchymal liver cells of rats treated with hepatotoxins. , 1989, Biochemical and biophysical research communications.

[74]  C. Cooper,et al.  Biosynthesis of the protein encoded by the c-met proto-oncogene. , 1989, Oncogene.

[75]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[76]  C. Meijer,et al.  Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy , 2005, Cancer Gene Therapy.

[77]  M. Makuuchi,et al.  Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. , 2005, Oncology reports.

[78]  A. Bardelli,et al.  Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). , 1994, Oncogene.

[79]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.